Schon MP, Boehncke WH: Psoriasis. N Engl J Med. 2005, 352 (18): 1899-1912. 10.1056/NEJMra041320.
Article
CAS
PubMed
Google Scholar
Naldi L: Epidemiology of psoriasis. Curr Drug Targets Inflamm Allergy. 2004, 3 (2): 121-128. 10.2174/1568010043343958.
Article
CAS
PubMed
Google Scholar
Kivelevitch DN, Hebeler KR, Patel M, Menter A: Emerging topical treatments for psoriasis. Expert Opin Emerg Drugs. 2013, 18 (4): 523-532. 10.1517/14728214.2013.861418.
Article
CAS
PubMed
Google Scholar
Balato N, Di Costanzo L, Ayala F, Balato A, Sanduzzi A, Bocchino M: Psoriatic disease and tuberculosis nowadays. Clin Dev Immunol. 2012, 2012: 747204-10.1155/2012/747204.
Article
PubMed
PubMed Central
Google Scholar
Daudén E, Castañeda S, Suárez C, García-Campayo J, Blasco AJ, Aguilar MD, Ferrándiz C, Puig L, Sánchez-Carazo JL, Working Group on Comorbidity in Psoriasis: Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis. J Eur Acad Dermatol Venereol. 2013, 27 (11): 1387-1404. 10.1111/jdv.12024. doi:10.1111/jdv.12024
Article
PubMed
Google Scholar
Picardi M, De Rosa G, Selleri C, Pane F, Rotoli B, Muretto P: Clinical relevance of intrahepatic hepatitis B virus DNA in HBsAg-negative HBcAb-positive patients undergoing hematopoietic stem cell transplantation for haematological malignancies. Transplantation. 2006, 82 (1): 141-142. 10.1097/01.tp.0000225828.27850.fc.
Article
PubMed
Google Scholar
Sansone S, Guarino M, Castiglione F, Rispo A, Auriemma F, Loperto I, Rea M, Caporaso N, Morisco F: Hepatitis B and C virus reactivation in immunosuppressed patients with inflammatory bowel disease. World J Gastroenterol. 2014, 20 (13): 3516-3524. 10.3748/wjg.v20.i13.3516.
Article
PubMed
PubMed Central
Google Scholar
Liang R, Lau G, Kwong Y: Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J Clin Oncol. 1999, 17 (1): 394-398.
CAS
PubMed
Google Scholar
Persico M, De Marino F, Di Giacomo Russo G, Morante A, Rotoli B, Torella R, De Renzo A: Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin lymphoma. Blood. 2002, 99 (2): 724-725. 10.1182/blood.V99.2.724.
Article
CAS
PubMed
Google Scholar
Dervite I, Hober D, Morel P: Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med. 2001, 344 (1): 68-69. 10.1056/NEJM200101043440120.
Article
CAS
PubMed
Google Scholar
Francisci D, Falcinelli F, Schiaroli E, Capponi M, Belfiori B, Flenghi L, Baldelli F: Management of hepatitis B virus reactivation in patients with hematological malignancies treated with chemotherapy. Infection. 2010, 38 (1): 58-61. 10.1007/s15010-009-9019-1.
Article
CAS
PubMed
Google Scholar
Yağci M, Ozkurt Z, Yeğin Z, Aki Z, Sucak GT, Haznedar R: Hepatitus B virus reactivation in HBV-DNA negative and positive patients with hematological malignancies. Hematology. 2010, 15 (4): 240-244. 10.1179/102453309X12583347114059.
Article
PubMed
Google Scholar
Sugauchi F, Tanaka Y, Kusumoto S, Matsuura K, Sugiyama M, Kurbanov F, Ueda R, Mizokami M: Virological and clinical characteristics on reactivation of occult hepatitis B in patients with hematological malignancy. J Med Virol. 2011, 83 (3): 412-418. 10.1002/jmv.21995.
Article
CAS
PubMed
Google Scholar
Picardi M, Pane F, Quintarelli C, De Renzo A, Del Giudice A, De Divitiis B, Persico M, Ciancia R, Salvatore F, Rotoli B: Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkin’s lymphomas: high prevalence of acquired viral genomic mutations. J Haematol. 2003, 88 (11): 1296-1303.
CAS
Google Scholar
Huang Y, Lin H, Lee S: Management of chemotherapy-induced hepatitis B virus reactivation. J Chin Med Assoc. 2012, 75 (8): 359-362. 10.1016/j.jcma.2012.06.006.
Article
PubMed
Google Scholar
Lee I, Huang Y, Chu C, Lee PC, Lin HC, Lee SD: Hepatitis B virus reactivation after 23 months of rituximab-based chemotherapy in an HBsAg-negative, anti-HBs-positive patient with follicular lymphoma. J Chin Med Assoc. 2010, 73 (3): 156-160. 10.1016/S1726-4901(10)70031-9.
Article
PubMed
Google Scholar
Hui C, Cheung W, Zhang H, Au WY, Yueng YH, Leung AY, Leung N, Luk JM, Lie AK, Kwong YL, Liang R, Lau GK: Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology. 2006, 131 (1): 59-68. 10.1053/j.gastro.2006.04.015.
Article
CAS
PubMed
Google Scholar
Wu J, Huang Y, Lee P, Lin HC, Lee SD: Fatal reactivation of hepatitis B virus in a patient who was hepatitis B surface antigen negative and core antibody positive before receiving chemotherapy for non-Hodgkin lymphoma. J Clin Gastroenterol. 2009, 43 (5): 496-498. 10.1097/MCG.0b013e3181945942.
Article
CAS
PubMed
Google Scholar
Koskinas J, Tampaki M, Doumba PP, Rallis E: Hepatitis B virus reactivation during therapy with ustekinumab for psoriasis in a hepatitis B surface-antigen-negative anti-HBs-positive patient. Br J Dermatol. 2013, 168 (3): 679-680. 10.1111/bjd.12120.
Article
CAS
PubMed
Google Scholar
Fotiadou C, Lazaridou E, Ioannides D: Safety of anti-tumour necrosis factor- agents in psoriasis patients who were chronic hepatitis B carriers: a retrospective report of seven patients and brief review of the literature. JEADV. 2011, 25 (4): 471-474.
CAS
PubMed
Google Scholar
Marinos G, Naoumov NV, Rossol S, Torre F, Wong PY, Gallati H, Portmann B, Williams R: Tumor necrosis factor receptors in patients with chronic hepatitis B virus infection. Gastroenterology. 1995, 108 (5): 1453-1463. 10.1016/0016-5085(95)90694-0.
Article
CAS
PubMed
Google Scholar
Cassano N, Mastrandrea V, Principi M, Loconsole F, De Tullio N, Di Leo A, Vena GA: Anti-tumor necrosis factor treatment in occult hepatitis B virus infection: a retrospective analysis of 62 patients with psoriatic disease. J Biol Regul Homeost Agents. 2011, 25 (2): 285-289.
CAS
PubMed
Google Scholar
Prignano F, Ricceri F, Pescitelli L, Zanieri F, Lotti T: Tumour necrosis factor-a antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients. Br J Dermatol. 2011, 164 (3): 645-647.
CAS
PubMed
Google Scholar
Navarro R, Vilarrasa E, Herranz P, Puig L, Bordas X, Carrascosa JM, Taberner R, Ferrán M, García-Bustinduy M, Romero-Maté A, Pedragosa R, García-Diez A, Daudén E: Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting. Br J Dermatol. 2013, 168 (3): 609-616. 10.1111/bjd.12045.
Article
CAS
PubMed
Google Scholar
Chiu HY, Chen CH, Wu MS, Cheng YP, Tsai TF: The safety profile of ustekinumab in the treatment of psoriasis patients with concurrent hepatitis B or hepatitis C. Br J Dermatol. 2013, 169 (6): 1295-1303. 10.1111/bjd.12461.
Article
CAS
PubMed
Google Scholar
Navarro R, Concha-Garzon MJ, Castano C, Casal C, Guiu A, Daudén E: Outcome of patients with serology suggestive of past hepatitis B virus infection during antitumor necrosis factor therapy for psoriasis. Intern J Dermatol. 2014, 65: 1241-1245.
Google Scholar
Costa L, Caso F, Atteno M, Giannitti C, Spadaro A, Ramonda R, Vezzù M, Del Puente A, Morisco F, Fiocco U, Galeazzi M, Punzi L, Scarpa R: Long-term safety of anti-TNF-α in PsA patients with concomitant HCV infection: a retrospective observational multicenter study on 15 patients. Clin Rheumatol. 2014, 33 (2): 273-276. 10.1007/s10067-013-2378-0.
Article
PubMed
Google Scholar
Navarro R, Concha-Garzón MJ, Castaño C, Casal C, Guiu A, Daudén E. Outcome of patients with serology suggestive of past hepatitis B virus infection during antitumor necrosis factor therapy for psoriasis. Int J Dermatol. 2014 Feb 14. doi:10.1111/ijd.12313. [Epub ahead of print]
European Association for the Study of the Liver: EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012, 57: 167-185.
Article
Google Scholar
European Association for the Study of the Liver: EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol. 2014, 60 (2): 392-420. 10.1016/j.jhep.2013.11.003.
Article
Google Scholar
Masarone M, De Renzo A, La Mura V, Sasso FC, Romano M, Signoriello G, Rosato V, Perna F, Pane F, Persico M: Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma. BMC Gastroenterol. 2014, 14: 31-10.1186/1471-230X-14-31.
Article
PubMed
PubMed Central
Google Scholar
Morisco F, Castiglione F, Rispo A, Stroffolini T, Sansone S, Vitale R, Guarino M, Biancone L, Caruso A, D'Inca R, Marmo R, Orlando A, Riegler G, Donnarumma L, Camera S, Zorzi F, Renna S, Bove V, Tontini G, Vecchi M, Caporaso N: Effect of immunosuppressive therapy on patients with inflammatory bowel diseases and hepatitis B or C virus infection. J Viral Hepat. 2013, 20 (3): 200-208. 10.1111/j.1365-2893.2012.01643.x.
Article
CAS
PubMed
Google Scholar
Modesti V, Ramonda R, Ortolan A, Lorenzin M, Lo Nigro A, Frallonardo P, Oliviero F, Campana C, Punzi L: Infection relapse in spondyloarthritis treated with biological drugs: a single-centre study. Scand J Rheumatol. 2012, 41 (6): 490-491. 10.3109/03009742.2012.698393.
Article
CAS
PubMed
Google Scholar
Núñez-Rodríguez MH, Santamaría-Martínez A, Mata-Román L, Caro-Patón A: Reactivation of hepatitis B treated with adefovir after infliximab administration. Med Clin (Barc). 2006, 126 (14): 558-559. 10.1157/13087150.
Article
Google Scholar
Pérez-Alvarez R, Díaz-Lagares C, García-Hernández F, Lopez-Roses L, Brito-Zerón P, Pérez-de-Lis M, Retamozo S, Bové A, Bosch X, Sanchez-Tapias JM, Forns X, Ramos-Casals M, BIOGEAS Study Group: Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore). 2011, 90 (6): 359-371. 10.1097/MD.0b013e3182380a76.
Article
Google Scholar
Dernis E, Lavie F, Salliot C, Flipo RM, Saraux A, Maillefert JF, Paul C, Goupille P, Cantagrel A, Claudepierre P, Gaudin P, Tebib J, Wendling D, Schaeverbeke T, Le Loët X, Combe B: Pharmacological treatment (biotherapy excluded) of peripheral psoriatic arthritis: development of recommendations for clinical practice based on data from the literature and experts opinion. Joint Bone Spine. 2009, 76 (5): 524-531. 10.1016/j.jbspin.2009.03.002.
Article
PubMed
Google Scholar
Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler D, Finlay AY, Griffiths CE, Jackson K, McHugh NJ, McKenna KE, Reynolds NJ, Ormerod AD, British Association of Dermatologists: British association of dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol. 2005, 153 (3): 486-497. 10.1111/j.1365-2133.2005.06893.x.
Article
CAS
PubMed
Google Scholar
Ohtsuki M, Terui T, Ozawa A, Morita A, Sano S, Takahashi H, Komine M, Etoh T, Igarashi A, Torii H, Asahina A, Nemoto O, Nakagawa H, Biologics Review Committee of the Japanese Dermatological Association: Japanese guidance for use of biologics for psoriasis (the 2013 version). J Dermatol. 2013, 40 (9): 683-695. 10.1111/1346-8138.12239.
Article
CAS
PubMed
Google Scholar